Highlights the essential importance of cell encapsulation technology in enabling effective, long-term ...
Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity economy is entering a massive repricing event as researchers confirm that metabolic dysfunction...
Announced a newly published study from the Mayo Clinic reinforces the critical role of the “longevity ...
Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related disorders, today announced...
Announced that its 50/50 joint venture with Austrianova has entered into an exclusive, worldwide License ...
VANCOUVER – Baystreet.ca News Commentary – The metabolic disorder therapeutics market projects growth to $120.7 billion by 2030 as biotechnology firms pioneer organ-level treatments addressing diabetes,...
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END
MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...
Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related disorders, today announced...
Announced the formation of a groundbreaking Joint Venture and License Agreement aimed at revolutionizing ...